Venmax Drugs Receives NCLT Nod for Hatri Pharma Amalgamation

NCLT Hyderabad approved the merger process; Venmax shareholders to vote on October 24, 2026.

Reader Takeaway: The merger seeks operational synergies and vertical integration, pending final shareholder and tribunal approval.

What just happened

The National Company Law Tribunal (NCLT), Hyderabad, has issued an order allowing Venmax Drugs and Pharmaceuticals to proceed with its Scheme of Amalgamation with Hatri Pharma Private Limited. The Tribunal has dispensed with the requirement for creditor meetings for both companies, clearing the path for the primary shareholder vote. Venmax Drugs is now required to conduct an equity shareholder meeting on October 24, 2026, via video conferencing to seek approval for the merger.

Why this matters

The scheme proposes a 1:1 share exchange ratio, meaning Hatri Pharma shareholders will receive one fully paid-up share of Venmax for each share they hold in the transferor company. Management expects this integration to improve operating margins through backward integration and create a more efficient distribution network. By consolidating resources and management expertise, the firm aims to reduce administrative overhead and streamline regulatory compliance.

Risks to watch

While the NCLT has granted its initial directions, the merger is not final. Success hinges on obtaining the necessary majority support from Venmax shareholders during the October 24 meeting. Additionally, the company must complete all further procedural filings and receive final sanctions from the Tribunal to conclude the legal amalgamation process.

Context metrics

As of March 31, 2026, Venmax Drugs reported an issued and paid-up capital of Rs 11.58 crore, while Hatri Pharma reported Rs 23.73 crore. The upcoming meeting will be chaired by Ms. Sarvani Desiraju, with Ms. Kruthi Kalaga appointed as the scrutinizer.